Glenmark Generics Inc. USA, a subsidiary of Glenmark Generics Limited, has informed that it has received a final ANDA approval from the United States Food and Drug Administration (USFDA) for its Hydralazine Hydrochloride tablets.

The product, which is generic equivalent of AB rated Pliva’s (Hydralazine Hydrochloride) is used in the treatment of hypertension. The company would sell the tablets in the active strengths of 10mg, 25mg, 50mg and 100mg.

According to IMS Health, Hydralazine Hydrochloride tablets had annual sales of USD 55 million for the period ending March 2009.

Glenmark has informed that it will immediately commence marketing and shipping their generic version in the US market.

The counter closed on Monday at Rs 225, marginally down compared to its previous close. The scrip has made 52-week-high and low of Rs 730 and Rs 119 respectively.